CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2024 FINANCIAL RESULTS
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, will release its second quarter 2024 financial results after market close on Tuesday, Aug. 6, 2024. A conference call will follow at 4:30 p.m. Eastern Time. The company focuses on providing unique products for hospital acute care, gastroenterology, and oncology markets. Cumberland's portfolio includes FDA-approved brands such as Acetadote®, Caldolor®, Kristalose®, Omeclamox®-Pak, Sancuso®, Vaprisol®, and Vibativ®. Additionally, Cumberland has Phase II clinical programs evaluating ifetroban for cardiomyopathy associated with Duchenne Muscular Dystrophy and Systemic Sclerosis, and recently received FDA clearance for a Phase II study in Idiopathic Pulmonary Fibrosis patients.
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), un'azienda farmaceutica specializzata, rilascerà i suoi risultati finanziari del secondo trimestre 2024 dopo la chiusura del mercato il martedì 6 agosto 2024. Seguirà una conferenza telefonica alle 16:30 ora orientale. L'azienda si concentra sulla fornitura di prodotti unici per le cure acute in ospedale, la gastroenterologia e i mercati oncologici. Il portafoglio di Cumberland include marchi approvati dalla FDA come Acetadote®, Caldolor®, Kristalose®, Omeclamox®-Pak, Sancuso®, Vaprisol® e Vibativ®. Inoltre, Cumberland ha programmi clinici di Fase II che valutano ifetroban per la cardiomiopatia associata alla distrofia muscolare di Duchenne e alla sclerosi sistemica, e ha recentemente ricevuto l'approvazione della FDA per uno studio di Fase II nei pazienti con fibrosi polmonare idiopatica.
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), una compañía farmacéutica especializada, anunciará sus resultados financieros del segundo trimestre de 2024 después del cierre del mercado el martes 6 de agosto de 2024. Seguirá una conferencia telefónica a las 4:30 p.m. Hora del Este. La empresa se centra en proporcionar productos únicos para el cuidado agudo en hospitales, gastroenterología y mercados de oncología. El portafolio de Cumberland incluye marcas aprobadas por la FDA como Acetadote®, Caldolor®, Kristalose®, Omeclamox®-Pak, Sancuso®, Vaprisol® y Vibativ®. Además, Cumberland tiene programas clínicos de Fase II que evalúan ifetroban para la cardiomiopatía asociada a la distrofia muscular de Duchenne y la esclerosis sistémica, y recientemente recibió la aprobación de la FDA para un estudio de Fase II en pacientes con fibrosis pulmonar idiopática.
컴벌랜드 제약 주식회사(Cumberland Pharmaceuticals Inc., Nasdaq: CPIX)는 전문 제약 회사로, 2024년 2분기 재무 실적을 2024년 8월 6일 화요일 시장 종료 후 발표할 예정이다. 동부 표준시 기준 오후 4시 30분에 전화 회의가 이어질 것이다. 회사는 병원 급성 치료, 위장병학 및 종양학 시장을 위한 독특한 제품 제공에 집중하고 있다. 컴벌랜드의 포트폴리오에는 Acetadote®, Caldolor®, Kristalose®, Omeclamox®-Pak, Sancuso®, Vaprisol®, Vibativ®와 같은 FDA 승인 브랜드가 포함되어 있다. 또한, 컴벌랜드는 두체네형 근이영양증 및 전신경화증과 관련된 심근병증에 대한 ifetroban을 평가하는 2상 임상 프로그램을 진행하고 있으며, 최근에는 특발성 폐섬유증 환자에 대한 2상 연구에 대해 FDA의 승인을 받았다.
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), une entreprise pharmaceutique spécialisée, publiera ses résultats financiers du deuxième trimestre 2024 après la fermeture du marché le mardi 6 août 2024. Une conférence téléphonique suivra à 16h30, heure de l'Est. L'entreprise se concentre sur la fourniture de produits uniques pour les soins aigus en milieu hospitalier, la gastro-entérologie et les marchés de l'oncologie. Le portefeuille de Cumberland comprend des marques approuvées par la FDA telles que Acetadote®, Caldolor®, Kristalose®, Omeclamox®-Pak, Sancuso®, Vaprisol® et Vibativ®. De plus, Cumberland a des programmes cliniques de phase II évaluant ifetroban pour la cardiomyopathie associée à la dystrophie musculaire de Duchenne et à la sclérose systémique, et a récemment reçu l'approbation de la FDA pour une étude de phase II chez des patients atteints de fibrose pulmonaire idiopathique.
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), ein auf Spezialpharmazeutika spezialisiertes Unternehmen, wird seine finanziellen Ergebnisse des zweiten Quartals 2024 nach Markt-schluss am Dienstag, den 6. August 2024 bekanntgeben. Darauf folgt um 16:30 Uhr Eastern Time eine Telefonkonferenz. Das Unternehmen konzentriert sich darauf, einzigartige Produkte für die akute Krankenhausversorgung, Gastroenterologie und Onkologie-Märkte bereitzustellen. Das Portfolio von Cumberland umfasst von der FDA genehmigte Marken wie Acetadote®, Caldolor®, Kristalose®, Omeclamox®-Pak, Sancuso®, Vaprisol® und Vibativ®. Darüber hinaus hat Cumberland Phase-II-Studienprogramme, die ifetroban bei kardiomyopathie im Zusammenhang mit der Duchenne-Muskeldystrophie und der systemischen Sklerose untersuchen, und erhielt kürzlich von der FDA die Genehmigung für eine Phase-II-Studie bei Patienten mit idiopathischer Lungenfibrose.
- Cumberland Pharmaceuticals has a diverse portfolio of seven FDA-approved brands
- The company is advancing multiple Phase II clinical programs for its ifetroban product candidate
- FDA clearance received for a new Phase II study in Idiopathic Pulmonary Fibrosis patients
- None.
A conference call will be held on Aug. 6 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BIfa6a94515e5548c28e9d77d03c95a13e.
Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference.
A replay of the call will be available for one year and can be accessed via Cumberland's website or by visiting https://edge.media-server.com/mmc/p/h9bx4zn8.
Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on providing unique products that improve patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments.
The company's portfolio of FDA-approved brands includes:
- Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning;
- Caldolor® (ibuprofen) injection, for the treatment of pain and fever;
- Kristalose® (lactulose) for oral solution, a prescription laxative, for the treatment of constipation;
- Omeclamox®-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease;
- Sancuso® (granisetron) transdermal system, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;
- Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and
- Vibativ® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy and Systemic Sclerosis. Additionally, Cumberland recently received FDA clearance to proceed directly to a Phase II study for patients with Idiopathic Pulmonary Fibrosis, the most common form of progressive fibrosing interstitial lung disease.
For more information on Cumberland's approved products, including full prescribing information, please visit links to the individual product websites, which can be found on the company's website at www.cumberlandpharma.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-to-announce-second-quarter-2024-financial-results-302210213.html
SOURCE Cumberland Pharmaceuticals
FAQ
When will Cumberland Pharmaceuticals (CPIX) release its Q2 2024 financial results?
What time is Cumberland Pharmaceuticals' (CPIX) Q2 2024 earnings conference call?
What are the main market segments Cumberland Pharmaceuticals (CPIX) focuses on?
What new FDA clearance did Cumberland Pharmaceuticals (CPIX) recently receive?
